CRDF
Cardiff Oncology, Inc.
Key Financials
Operating Income
$-48960000
↓ 0.6%
Net Income
$-45851000
↓ 0.9%
Revenue
$593000
↓ 13.2%
Total Liabilities
$16.5M
↑ 15.8%
Total Assets
$61.9M
↓ 36.3%
Shareholders' Equity
$45.4M
↓ 45.3%
Cash & Equivalents
$17.5M
↓ 66.1%
Operating Cash Flow
$-37923000.00
↓ 0.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 9/14/2026 | View on SEC |
| DEFA14A | 8/26/2026 | View on SEC |
| DEF 14A | 8/26/2026 | View on SEC |
| PRE 14A | 8/14/2026 | View on SEC |
| 8-K | 8/11/2026 | View on SEC |
| 10-Q | 8/11/2026 | View on SEC |
| SCHEDULE 13G/A | 7/27/2026 | View on SEC |
| S-8 | 7/21/2026 | View on SEC |
| 4 | 7/16/2026 | View on SEC |
| 4 | 7/16/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CRDF |
| Company Name | Cardiff Oncology, Inc. |
| CIK | 1213037 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 858-952-7570 |